Hyppigheden af CNS- blødninger i løbet af den 28- dages forsøgsperiode var henholdsvis 0, 2% og 0, 1% af de drotrecogin alfa (aktiveret) - behandlede og placebobehandlede patienter.
The incidence of CNS bleeds during the 28-day study period was 0.2% and 0.1% for drotrecogin alfa (activated)- treated and placebo-treated patients, respectively.